Fission yeast-based screening to identify putative HDAC inhibitors using a telomeric reporter strain

Molecules and Cells

Volumn 26, Issue 1, 2008, Pages 93-99

  Chung, Kyung Sook ^a   Ahn, Jiwon ^a   Choi, Chung Hae ^a   Yim, Nam Hui ^a   Kang, Chang Mo ^b   Kim, Chun Ho ^b   Lee, Kyeong ^a   Park, Hee Moon ^c   Song, Kyung Bin ^c   Won, Misun ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

HDAC inhibitor; Heterochromatin; Schizosaccharomyces pombe; Telomere; Yeast drug screen

Indexed keywords

1 PHENYL 4 (2,4,6, TRIMETYLHYLPHENYL)BUTYL 2 ENE 1,4 DIONE); ANTINEOPLASTIC AGENT; GELSOLIN; GENE PRODUCT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; N DECYL 2 (N DECYLCARBAMIMIDOYL METHYLDISULFANYL) ACETAMIDINE; PROTEIN P21; PROTEIN URA4; TRICHOSTATIN A; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; HISTONE; HYDROXAMIC ACID;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; FUNGAL STRAIN; GENE INSERTION; GENE SILENCING; HETEROCHROMATIN; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REPORTER GENE; SCHIZOSACCHAROMYCES POMBE; SCREENING TEST; TELOMERE; YEAST CELL BASED ASSAY; CELL CULTURE; CELL PROLIFERATION; CHROMATIN; COMBINATORIAL CHEMISTRY; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHYSIOLOGY; SCHIZOSACCHAROMYCES; TRANSACTIVATION;

SCHIZOSACCHAROMYCES POMBE; SCHIZOSACCHAROMYCETACEAE;

ACETYLATION; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; CHROMATIN; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GELSOLIN; GENE EXPRESSION REGULATION; GENE SILENCING; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; SCHIZOSACCHAROMYCES; TELOMERE; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC;

EID: 53449094815     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Allshire, R.C., Javerzat, J.P., Redhead, N.J., and Cranston, G. (1994). Position effect variegation at fission yeast centromeres. Cell 76, 157-169.
2. Allshire, R.C., Nimmo, E.R., Ekwall, K., Javerzat, J.P., and Cranston, G. (1995). Mutations derepressing silent centromeric domains in fission yeast disrupt chromosome segregation. Genes Dev. 9, 218-233.
3. Anto, R.J., Sukumaran, K., Kuttan, G., Rao, M.N., Subbaraju, V., and Kuttan, R. (1995). Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett. 97, 33-37.
4. Archer, S.Y., Meng, S., Shei, A., and Hodin, R.A. (1998). p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95, 6791-6796.
5. Benetti, R., Garcia-Cao, M., and Blasco, M.A. (2007). Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nat. Genet. 39, 243-250.
6. Bi, G., and Jiang, G. (2006). The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol. Immunol. 3, 285-290.
7. Boeck, P., Leal, P.C., Yunes, R.A., Filho, V.C., Lopez, S., Sortino, M., Escalante, A., Furlan, R.L., and Zacchino, S. (2005). Anti-fungal activity and studies on mode of action of novel xanthoxy-line-derived chalcones. Arch. Pharm. 338, 87-95.
8. Boulares, A.H., Yakovlev, A.G., Ivanova, V., Stoica, B.A., Wang, G., Iyer, S., and Smulson, M. (1999). Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J. Biol. Chem. 274, 22932-22940.
9. Cabrera, M., Simoens, M., Falchi, G., Lavaggi, M.L., Piro, O.E., Castellano, E.E., Vidal, A., Azqueta, A., Monge, A., de Cerain, A. L., et al. (2007). Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships. Bioorg. Med. Chem. 15, 3356-3367.
10. Chung, K.S., Won, M., Lee, S.B., Jang, Y.J., Hoe, K.L., Kim, D.U., Lee, J.W., Kim, K.W., and Yoo, H.S. (2001). Isolation of a novel gene from Schizosaccharomyces pombe: stm1+ encoding a seven-transmembrane loop protein that may couple with the heterotrimeric Galpha 2 protein, Gpa2. J. Biol. Chem. 276, 40190-40201.
11. Chung, K.S., Won, M., Lee, J.J., Ahn, J., Hoe, K.L., Kim, D.U., Song, K.B., and Yoo, H.S. (2007). Yeast-based screening to identify modulators of G-protein signaling using uncontrolled cell division cycle by overexpression of Stm1. J. Biotechnol. 129, 547-554.
12. Cianchi, F., Cortesini, C., Fantappie, O., Messerini, L., Schiavone, N., Vannacci, A., Nistri, S., Sardi, I., Baroni, G., Marzocca, C., et al. (2003). Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am. J. Pathol. 162, 793-801.
13. Cress, W.D., and Seto, E. (2000). Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184, 1-16.
14. Ekwall, K., Javerzat, J.P., Lorentz, A., Schmidt, H., Cranston, G., and Allshire, R. (1995). The chromodomain protein Swi6: a key component at fission yeast centromeres. Science 269, 1429-1431.
15. Forsburg, S.L. (2001). The art and design of genetic screens: yeast. Nat. Rev. Genet. 2, 659-668.
16. Guo, J.J., Li, Q.L., and Huang A.L. (2006). Histone deacetylation is involved in activation of CXCL10 upon IFNγ stimulation. Mol. Cells 22, 163-167.
17. Hall, I.M., Shankaranarayana, G.D., Noma, K., Ayoub, N., Cohen, A., and Grewal, S.I. (2002). Establishment and maintenance of a heterochromatin domain. Science 297, 2232-2237.
18. Han, J.W., Ahn, S.H., Park, S.H., Wang, S.Y., Bae, G.U., Seo, D.W., Kwon, H.K., Hong, S., Lee, H.Y., Lee, Y.W., et al. (2000). Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60, 6068-6074.
19. Hess-Stumpp, H. (2005). Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell Biol. 84, 109-121.
20. Hoshikawa, Y., Kwon, H.J., Yoshida, M., Horinouchi, S., and Beppu, T. (1994). Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res. 214, 189-197.
21. Huang, Y. (2002). Transcriptional silencing in Saccharomyces cerevisiae and Schizosaccharomyces pombe. Nucleic Acids Res. 30, 1465-1482.
22. Johnstone, R.W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299.
23. Kanoh, J., Sadaie, M., Urano, T., and Ishikawa, F. (2005). Telomere binding protein Taz1 establishes Swi6 heterochromatin independently of RNAi at telomeres. Curr. Biol. 15, 1808-1819.
24. Kouzarides, T. (1999). Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet Dev. 9, 40-48.
25. Lorentz, A., Ostermann, K., Fleck, O., and Schmidt, H. (1994). Switching gene swi6, involved in repression of silent mating-type loci in fission yeast, encodes a homologue of chromatin-associated proteins from Drosophila and mammals. Gene 143, 139-143.
26. Marchion, D., and Munster, P. (2007). Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 7, 583-598.
27. Marks, P., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T., and Kelly, W.K. (2001). Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202.
28. Marks, P.A., and Dokmanovic, M. (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497-1511.
29. Minucci, S., and Pelicci, P.G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51.
30. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83, 757-766.
31. Moreno, S., Klar, A., and Nurse, P. (1991). Molecular genetic analysis of fission yeast Schizosaccharomyces pombe. Methods Enzymol. 194, 795-823.
32. Myzak, M.C., and Dashwood, R.H. (2006). Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr. Drug Targets 7, 443-452.
33. Myzak, M.C., Ho, E., and Dashwood, R.H. (2006). Dietary agents as histone deacetylase inhibitors. Mol. Carcinog. 45, 443-446.
34. Nicholson, D.W. (1999). Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6, 1028-1042.
35. Nimmo, E.R., Cranston, G., and Allshire, R.C. (1994). Telomere-associated chromosome breakage in fission yeast results in variegated expression of adjacent genes. EMBO J. 13, 3801-3811.
36. Richards, E.J., and Elgin, S.C. (2002). Epigenetic codes for heterochromatin formation and silencing: rounding up the usual sus- pects. Cell 108, 489-500.
37. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., and Marks, P.A. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014-10019.
38. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. (1999). A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96, 4592-4597.
39. Sherman, F. (2002). Getting started with yeast. Methods Enzymol. 350, 3-41.
40. Thomsen, L.L., Scott, J.M., Topley, P., Knowles, R.G., Keerie, A.J., and Frend, A.J. (1997). Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400 W, a novel inhibitor. Cancer Res. 57, 3300-3304.
41. Thon, G., and Verhein-Hansen, J. (2000). Four chromo-domain proteins of Schizosaccharomyces pombe differentially repress transcription at various chromosomal locations. Genetics 155, 551-568.
42. Vasudevan, A., Ji, Z., Frey, R.R., Wada, C.K., Steinman, D., Heyman, H.R., Guo, Y., Curtin, M.L., Guo, J., Li, J., et al. (2003). Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 13, 3909-3913.
43. Woo, M., Hakem, R., Soengas, M.S., Duncan, G.S., Shahinian, A., Kagi, D., Hakem, A., McCurrach, M., Khoo, W., Kaufman, S.A., et al. (1998). Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 12, 806-819.
44. Woo, H.J., Lee, S.J., Choi, B.T., Park, Y.M., and Choi, Y.H. (2007). Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp. Mol. Pathol. 82, 77-84.
45. Yoshida, M., Horinouchi, S., and Beppu, T. (1995). Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17, 423-430.